These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23478571)

  • 1. Evaluation of the use of low-molecular-weight heparin in neonates: a retrospective, single-center study.
    Chander A; Nagel K; Wiernikowski J; Paes B; Chan AK;
    Clin Appl Thromb Hemost; 2013 Sep; 19(5):488-93. PubMed ID: 23478571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
    Michaels LA; Gurian M; Hegyi T; Drachtman RA
    Pediatrics; 2004 Sep; 114(3):703-7. PubMed ID: 15342842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
    Corder A; Held K; Oschman A
    Pediatr Blood Cancer; 2014 Jun; 61(6):1063-7. PubMed ID: 24375987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
    Malowany JI; Knoppert DC; Chan AK; Pepelassis D; Lee DS
    Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low molecular weight heparin dosing and monitoring in solid organ transplant recipients.
    Moten MA; Gaber AO; Putney D; Patel SJ
    Clin Transplant; 2013; 27(6):852-7. PubMed ID: 24033530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of anti-Xa in pregnant patients with mechanical prosthetic valves receiving low-molecular-weight heparin: peak or trough levels?
    Goland S; Schwartzenberg S; Fan J; Kozak N; Khatri N; Elkayam U
    J Cardiovasc Pharmacol Ther; 2014 Sep; 19(5):451-6. PubMed ID: 24607762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
    Bauman ME; Black KL; Bauman ML; Belletrutti M; Bajzar L; Massicotte MP
    Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of pregnant women with mechanical heart valve prosthesis: thromboprophylaxis with low molecular weight heparin.
    Abildgaard U; Sandset PM; Hammerstrøm J; Gjestvang FT; Tveit A
    Thromb Res; 2009 Jul; 124(3):262-7. PubMed ID: 19162303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective evaluation of enoxaparin dosing in patients 48 weeks' postmenstrual age or younger in a neonatal intensive care unit.
    Hicks JK; Shelton CM; Sahni JK; Christensen ML
    Ann Pharmacother; 2012; 46(7-8):943-51. PubMed ID: 22828970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluctuations of anti-Xa concentrations during maintenance enoxaparin therapy for neonatal thrombosis.
    Lulic-Botica M; Rajpurkar M; Sabo C; Tutag-Lehr V; Natarajan G
    Acta Paediatr; 2012 Apr; 101(4):e147-50. PubMed ID: 22211705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment of thrombosis with enoxaparin in pediatric and adolescent patients.
    Merkel N; Gunther G; Schobess R
    Acta Haematol; 2006; 115(3-4):230-6. PubMed ID: 16549901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children.
    Wysocki EL; Kuhn A; Steinbrenner J; Tyrrell L; Abdel-Rasoul M; Dunn A; Cloyd C
    J Pediatr Hematol Oncol; 2021 Oct; 43(7):e946-e950. PubMed ID: 33512867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability.
    Kitchen S; Iampietro R; Woolley AM; Preston FE
    Thromb Haemost; 1999 Oct; 82(4):1289-93. PubMed ID: 10544915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit?
    Sanchez de Toledo J; Gunawardena S; Munoz R; Orr R; Berry D; Sonderman S; Krallman S; Shiderly D; Wang L; Wearden P; Morell VO; Chrysostomou C
    Cardiol Young; 2010 Apr; 20(2):138-43. PubMed ID: 20199704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic dosing adjustment in pregnancy based upon measurements of anti-factor Xa levels.
    Gyamfi C; Cohen R; Desancho MT; Gaddipati S
    J Matern Fetal Neonatal Med; 2005 Nov; 18(5):329-31. PubMed ID: 16390793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers.
    Eriksson BI; Söderberg K; Widlund L; Wandeli B; Tengborn L; Risberg B
    Thromb Haemost; 1995 Mar; 73(3):398-401. PubMed ID: 7667822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulant effect at the time of epidural catheter removal in patients receiving twice-daily or once-daily low-molecular-weight heparin and continuous epidural analgesia after orthopedic surgery.
    Douketis JD; Kinnon K; Crowther MA
    Thromb Haemost; 2002 Jul; 88(1):37-40. PubMed ID: 12152674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low molecular weight heparins in patients with renal insufficiency.
    Symes J
    CANNT J; 2008; 18(2):55-61. PubMed ID: 18669012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Error in body weight estimation leads to inadequate parenteral anticoagulation.
    dos Reis Macedo LG; de Oliveira L; Pintão MC; Garcia AA; Pazin-Filho A
    Am J Emerg Med; 2011 Jul; 29(6):613-7. PubMed ID: 20825842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.